Clinical studyCutaneous ulcers associated with Hydroxyurea (cas 127-07-1) therapy

Add time:09/30/2019    Source:sciencedirect.com

Hydroxyurea (cas 127-07-1) is an antitumoral drug mainly used in the treatment of Philadelphia chromosome-negative myeloproliferative syndromes and sickle-cell disease. Ulcers represent a rare but severe long-term adverse effect of hydroxyurea therapy.Hydroxyurea-induced ulcers are often multiple and bilateral, typically developing in the perimalleolar region, although any cutaneous district is potentially affected. They generally look small, well-defined, shallow with an adherent, yellow, fibrinous necrotic base. A constant finding is also an extremely intense, treatment-resistant pain accompanying these ulcerations. Withdrawal of the drug generally leads to spontaneous healing of these lesions.Care providers tend to show insufficient awareness of this highly debilitating cutaneous side effect, and late or missed diagnoses are frequent. Instead, regular dermatologic screening should be performed on hydroxyurea-treated patients.This article will present a comprehensive review of indexed case reports and clinical studies, followed by a discussion about treatment options aiming at increasing knowledge about this specific topic.

We also recommend Trading Suppliers and Manufacturers of Hydroxyurea (cas 127-07-1). Pls Click Website Link as below: cas 127-07-1 suppliers

Prev:Real-life experience with Hydroxyurea (cas 127-07-1) in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent
Next:Influencing factors of intercalation of Potassium Acetate (cas 127-08-2) into dickite using immersion method)